CompletedPhase 2/3

Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)

Iran42 participantsStarted 2020-08-22

Plain-language summary

Approximately 17% of all patients with stroke are classified as having ESUS, which is associated with a considerable rate of stroke recurrence 4-5 % per year. Despite recent scientific advances in acute ischemic stroke treatment in recent decades,consensus treatment of all guidelines is still ASA

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. signing the inform consent
. recent ischemic stroke ( 7-60) days with criteria of ESUS
. only one risk factors of potential embolic source including:
. PTFV1 in standard ECG ≥0.05 mm.s or ≥0.005 mv.s
. LVH in standard ECG( Sokolow index≥ 35 mm) or on echocardiography
. Moderate or severe valvular disorder on echocardiography (except MS)
. PFO without indication of occlusion
. Left atrium enlargement in echocardiography

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Rate of stroke recurrence

Timeframe: Rate of stroke recurrence during one year fallow up

Rate of major bleeding

Timeframe: During 1 year of study

Trial details

NCT IDNCT04273516

SponsorMazandaran University of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-04-10

View on ClinicalTrials.gov More Stroke trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. signing the inform consent
. recent ischemic stroke ( 7-60) days with criteria of ESUS
. only one risk factors of potential embolic source including:
. PTFV1 in standard ECG ≥0.05 mm.s or ≥0.005 mv.s
. LVH in standard ECG( Sokolow index≥ 35 mm) or on echocardiography
. Moderate or severe valvular disorder on echocardiography (except MS)
. PFO without indication of occlusion
. Left atrium enlargement in echocardiography

Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)

Plain-language summary

Who can participate

Inclusion criteria

Questions worth asking your doctor

Questions for the trial coordinator

What they're measuring

Trial details

Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)

Plain-language summary

Who can participate

Inclusion criteria

Questions worth asking your doctor

Questions for the trial coordinator

What they're measuring

Trial details

Exclusion criteria